Original Article Cytokine production of papillary thyroid carcinoma coexisting with Hashimoto's thyroiditis

Liuhong Shi^{1*}, Liang Zhou^{1*}, Jianbiao Wang¹, Feibo Li², Lei Xie¹

¹Department of Head and Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; ²Second Department of General Surgery, Zhejiang Putuo Hospital, Zhoushan, Zhejiang Province, China. ^{*}Equal contributors.

Received May 31, 2017; Accepted July 27, 2017; Epub September 1, 2017; Published September 15, 2017

Abstract: In the tumor microenvironment coexisting with Hashimoto's thyroiditis (HT), cytokines secreted by the tumor cells, stroma cells, or immune cells play a critical role in the regulation of tumor growth, invasion, and metastasis. The present study aims to understand cytokine production from cancerous tissues (CT), para-cancerous tissues (PT), and serum in patients with papillary thyroid carcinoma (PTC) with or without accompanying HT. Using a multiplexed human cytokine assay, we found that nine cytokines, including Interleukin-1alpha (IL-1 α), Interleukin-1beta (IL-1β), Interleukin-12p70 (IL-12p70), Interleukin-8 (IL-8), Interferon-inducible protein-10 (IP-10), Monocyte chemoattractant protein-1 (MCP-1), Macrophage inflammatory protein-1alpha (MIP-1a), Macrophage inflammatory protein-1beta (MIP-1β), and soluble E-selectin (sE-Selectin), showed significantly higher expression in paracancerous tissues of HT⁺PTC compared with HT⁻PTC (P<0.05). In addition, H&E staining showed immune cell infiltration in PT but not in CT. Moreover para-cancerous tissues of HT*PTC patients produced more Interferon-alpha (IFN-a) (P=0.048) and Interferon-gamma (IFN-y) (P=0.004) compared with cancerous tissues, and production of Intercellular cell adhesion molecule-1 (ICAM-1) was significantly higher in CT than PT both in HT+PTC (P=0.001) and HTPTC (P=0.012) patients. To conclude, autoimmune HT was found to affect the cytokine profiles in patients with PTC by stimulating secretion of Th1-type cytokines and chemokines, but further studies are needed to determine the significance of these findings and to reveal the exact mechanism of the interactions between chemokines and cytokines in the pathogenesis of HT and PTC.

Keywords: Hashimoto's thyroiditis, papillary thyroid carcinoma, cytokine, chemokine

Introduction

Hashimoto's thyroiditis (HT) is the most frequent autoimmune disease and is characterized by a cellular immune response with lymphatic infiltration of the thyroid gland by T and B cells, as well as a humoral immune response leading to specific antibody production of thyroglobulin (TgAb) and thyroperoxidase (TPOAb) and destruction of thyroid follicles.

Thyroid cancer is the most common endocrine malignancy and papillary thyroid carcinoma (PTC) accounts for 85% to 90% of cases. Moreover, the incidence of PTC has increased 3-fold over the last 3 decades [1] and a parallel increase in the incidence of autoimmune thyroid diseases such as HT has been observed. Because coexistence of HT and PTC in the thyroid gland is often found in the clinic, debate about the relationship between these diseases has continued since Dailey first proposed it in 1955 [2].

The connection between a chronic inflammatory immune response and tumorigenesis has been extensively investigated during the past decade and some mechanisms have been elucidated, such as the association between viral hepatitis B or C and liver cancer and between Crohn's disease and colon cancer. Likewise, a retrospective Chinese cohort study showed that PTC with HT was associated with increased prevalence of multi-focal disease and capsular invasion [3], suggesting the need to further analyze the thyroid microenvironment of HT.

In the tumor microenvironment coexisting with HT, cytokines secreted by the tumor cells, stroma cells, or immune cells play a critical role in




Figure 1. Representative hematoxylin and eosin-stained sections of cancerous tissues and para-cancerous tissues (40× magnification). A. Cancerous tissue (HT⁺PTC): few immune cells; B. Para-cancerous tissue (HT⁺PTC): immune cells infiltrated into para-cancerous tissues with distinct lymphoid follicular (LF) growth; C. Cancerous tissue (HT⁻PTC): very few infiltrated immune cells; D. Para-cancerous tissue (HT⁻PTC): almost no infiltrated immune cells.

the regulation of tumor growth, invasion, and metastasis. The present study aims to understand cytokine production from cancerous tissues (CT), para-cancerous tissues (PT), and serum in patients with PTC with or without accompanying HT.

Materials and methods

Patient selection

This study was approved by the local ethical committees and all patients provided informed consent before blood collection and surgery. Patients who were diagnosed with PTC, irrespective of accompanying HT, and underwent thyroidectomy or lobectomy between May 2016 and October 2016 at the Department of Head and Neck Surgery, Sir Run Run Shaw Hospital, were identified as eligible for the study. After the operation, histological diagnosis of PTC and

HT was confirmed by two experienced pathologists from the Department of Pathology of the same hospital.

The patients involved in this study met the following criteria: no previous thyroid surgery, pregnancy, infection, other autoimmune disease, or other malignancies at the time of the investigation. All patients were selected randomly. Finally, 22 patients were enrolled in the study: 11 women and 10 men aged from 24 to 67 years with average age of 43. Patients with PTC were divided into two groups: PTC patients with Hashimoto's thyroiditis (HT⁺PTC group, 13 patients) and PTC patients without coexisting Hashimoto's thyroiditis (HT-PTC group, 9 patients). Because the tumor sizes in some enrolled patients were too small for analysis, we examined 18 cancerous tissues and serum samples $(12 \text{ HT}^+\text{PTC}, 6 \text{ HT}^-\text{PTC}).$

choco bethech the two groups								
Cytokine	HT ⁺ PTC (n=13) x ± SD	HTPTC (n=9) x ± SD	Value of P					
ICAM-1	76012.5 ± 22340.5	75850.7 ± 32882.2	0.989					
IFN-γ	3.7 ± 1.8	2.2 ± 1.4	0.064					
IFN-α	1.8 ± 0.5	1.6 ± 0.6	0.382					
IL-1α	17.4 ± 5.2	9.8 ± 3.6	0.001					
IL-1β	25.2 ± 7.4	2.1 ± 1.7	0.001					
IL-12p70	6.8 ± 3.2	4.2 ± 1.9	0.026					
IL-8	190.1 ± 68.0	104.7 ± 41.2	0.003					
IP-10	518.0 ± 168.9	265.6 ± 65.5	0.001					
MCP-1	3097.7 ± 1244.2	2109.4 ± 653.0	0.026					
MIP-1α	83.7 ± 19.8	47.5 ± 18.9	0.001					
ΜΙΡ-1β	432.2 ± 164.8	223.8 ± 118.7	0.004					
sE-Selectin	7792.5 ± 2219.0	4100.1 ± 1677.3	0.001					

Table 1. Cytokine concentrations in para-cancerous tissues of

 PTC patients with or without Hashimoto thyroiditis and differences between the two groups

Sample preparation

Serum and tissue samples were collected from each patient. Specifically, for serum sample preparation, fasting blood samples were collected 1 day before operation and the blood was allowed to clot for 20-30 min at 20-25°C. The clotted blood samples were centrifuged at 1000×g for 10 min at 20-25°C and the serum fraction was collected and stored at -80°C. For tissue sample preparation, papillary thyroid carcinoma tissues and para-cancerous tissues (2 cm from cancerous tissues), which were confirmed to contain no cancer cells by two experienced pathologists, were collected during surgery and immediately placed in liquid nitrogen until analysis.

Hematoxylin-eosin staining

Thyroid carcinoma tissues and nearby normal tissues were sent immediately to the Department of Pathology. Tissues were fixed in 10% neutral buffered formalin at 4°C overnight, dehydrated, and embedded in paraffin. Section slides were stained with hematoxylin-eosin (H&E) for pathological diagnosis [4].

Cytokine quantification

Cytokine levels in tissue homogenates and serum were measured using the Procarta Plex Multiplex Immunoassay kit (Affymetrix, eBiosciences, USA) according to the user manual. This multiplexed protein measurement used magnetic bead technology from Luminex to measure concentrations of ICAM-1, IFN- γ , IFN- α , IL-1 α , IL-1 β , IL-12p70, IL-8, IP-10, MCP-1, MIP-1 α , MIP-1 β , and sE-Selectin.

Statistical analysis

Data were analyzed by SPSS software version 23.0 (SPSS, Inc., Chicago, IL, USA). Statistical analyses were performed using the t test. Quantitative data are displayed as the mean and standard deviation (SD). Differences with p values <0.05 were defined as statistically significant.

Results

Abundant immune cells infiltrated into para-cancerous tissues of HT⁺PTC patients

H&E staining results showed that immune cells only infiltrated into

the para-cancerous tissues and not the cancerous tissues in HT⁺PTC patients. Furthermore, some lymphoid germinal centers, which can often be seen as secondary lymphoid follicles (LF), were observed in the adjacent non-neoplastic parenchyma of PTC patients with severe HT (**Figure 1A** and **1B**). No immune cells could be found in para-cancerous tissues and cancerous tissues of HT⁻PTC patients by optical microscopy (**Figure 1C** and **1D**).

Increased levels of IL-1 α , IL-1 β , IL-12p70, IL-8, IP-10, MCP-1, MIP-1 α , MIP-1 β , and sE-Selectin in para-cancerous tissues of HT⁺PTC patients

Levels of 12 cytokines in cancerous tissues, para-cancerous tissues, and serum from PTC patients with or without HT were analyzed. The level of 9 cytokines (IL-1 α , IL-1 β , IL-12p70, IL-8, IP-10, MCP-1, MIP-1 α , MIP-1 β , and sE-Selectin) in para-cancerous tissues was significantly higher (P<0.05) in HT*PTC patients than in HT*PTC patients (**Table 1**; **Figure 2**); however, there was no difference (P≥0.05) between the two groups for cytokine levels in cancerous tissues and serum, which might be explained by the small sample size and high inter-individual variation among patients.

Differences in cytokine levels between cancerous tissues and para-cancerous tissues of HT⁺PTC and HT⁻PTC groups

Para-cancerous tissues of HT⁺PTC patients produced more IFN- α (P=0.048) and IFN- γ (P=0.004) compared with cancerous tissues. In addition, production of ICAM-1 was signifi-

Int J Clin Exp Pathol 2017;10(9):9567-9574




Figure 2. Higher expression levels of (A) IL-1 α , (B) IL-1 β , (C) IL-12p70, (D) IL-8, (E) IP-10, (F) MCP-1, (G) MIP-1 α , (H) MIP-1 β and (I) sE-Selectin in para-cancerous tissues of PTC patients with HT compared with those without HT (t-test, *P<0.05, **P≤0.01, ***P≤0.001).

cantly higher in cancerous tissues than paracancerous tissues both in HT⁺PTC (P=0.001) and HT⁻PTC (P=0.012) patients (**Figure 3**; **Table 2**).

Discussion

Cytokines are multifunctional cell signaling molecules that are produced in response to inflammation, infection, and cellular trauma [5, 6]. They may affect the cells they were secreted from, other cells nearby, or even influence the whole body. These actions play a significant role in maintaining homeostasis via complex interactions of the nervous, endocrine, and immune systems [7, 8]. In addition, cytokines are thought to mediate the origination and perpetuation of autoimmune thyroid disease, especially Hashimoto's thyroiditis. Moreover, some cytokines have a close correlation with the initiation and progression of cancer [9, 10].

It is traditionally assumed that the immune functional imbalance between T-helper 1 cell (Th1) and T-helper 2 cell (Th2) leads to tumor growth. In the report of Phenekos, the preferential expression of IL-2, IFN-y, IL-12, and IL-18, a Th1 pattern of immune response, which is characteristic of cellular immunity, is dominant in HT. In the same way, our study showed that the HT⁺PTC patients presented higher levels of IL-1 α , IL-1 β , and IL-12p70, which are also Th1 pattern cytokines, in para-cancerous tissues compared with HT-PTC patients (P=0.001, P=0.001, P=0.026, respectively). The preferential expression of IL-12 can promote CD4⁺T lymphocytes to differentiate into Th1 cells. IL-1 has been found to stimulate thyroid cell proliferation and modify thyroid epithelial tightness by altering the expression, localization, and organization of junction proteins, confirming the important role played by IL-1 β in the process of




 Table 2. Cytokine concentrations in cancerous tissues and para-cancerous tissues of PTC patients

 with or without Hashimoto thyroiditis and differences between cancerous tissues and para-cancerous tissues

	PTC with HT			PTC without HT		
Cytokine	Cancerous Tissue (n=12) x ± SD	Para-cancerous Tissue (n=13) x ± SD	Value of P	Cancerous Tissue (n=6) x ± SD	Para-cancerous Tissue (n=9) x ± SD	Value of P
ICAM-1	228184.8 ± 62529.1	76012.5 ± 22340.5	0.001	211812.7 ± 89759.9	75850.7 ± 32882.2	0.012
IFN-γ	1.9 ± 0.8	3.9 ± 2.0	0.004	2.3 ± 0.7	2.2 ± 1.4	0.974
IFN-α	1.4 ± 0.4	1.8 ± 0.5	0.048	1.5 ± 0.3	1.6 ± 0.6	0.770
IL-1α	21.7 ± 11.7	18.2 ± 9.4	0.415	19.0 ± 13.6	10.9 ± 6.1	0.136
IL-1β	18.6 ± 19.1	25.2 ± 7.4	0.261	10.9 ± 10.5	2.1 ± 1.7	0.094
IL-12p70	5.6 ± 1.4	6.8 ± 3.2	0.218	5.8 ± 2.1	4.2 ± 1.9	0.144
IL-8	289.2 ± 173.2	190.1 ± 68.0	0.085	191.1 ± 105.1	104.7 ± 41.2	0.103
IP-10	414.4 ± 272.7	518.0 ± 168.9	0.261	317.9 ± 193.1	265.6 ± 65.5	0.548
MCP-1	2257.6 ± 1024.2	3097.7 ± 1244.2	0.080	2308.5 ± 810.0	2109.4 ± 653.0	0.607
MIP-1α	97.5 ± 26.8	83.7 ± 19.8	0.153	148.8 ± 171.6	47.5 ± 18.9	0.208
MIP-1β	628.9 ± 702.3	432.2 ± 164.8	0.362	384.6 ± 235.3	223.8 ± 118.7	0.168
sE-Selectin	6783.0 ± 2984.7	7792.5 ± 2219.0	0.345	6763.0 ± 2831.6	4100.1 ± 1677.3	0.038

carcinogenesis [11, 12]. However, IL-1 β plays a role in suppressing proliferation and reducing the invasive potential of human PTC cells [13]. We think this conflict actually accord with the clinical findings: PTC coexisting with HT is strongly associated with tumor multifocality, the absence of extrathyroidal extension, absence of lymph node metastasis, and high recurrence-free survival rates [14].

It has been suggested that E-selectin is related to the mechanism of neoplastic progression and metastasis [15]. Some investigators have reported a strong association between Eselectin expression and the presence of extrathyroidal extension [16], which correlated with the features of HT. Chronic inflammation probably contributes to tumor generation through increasing the secretion of E-selectin.

Chemokines are a family of small cytokines or signaling proteins that act as chemo-attractants to guide cell migration. Chemokines are functionally divided into two groups: one is the homeostatic chemokine, which is produced in certain tissues and is responsible for basal leukocyte migration; the other is the inflammatory chemokine (IL-8, IP-10, MCP-1, MIP-1 α , MIP-1 β), which is produced under pathological conditions (or pro-inflammatory stimuli such as IL-1 or viruses) and actively participates in the inflammatory response by attracting immune cells to the site of inflammation.

According to the arrangement of Cysteine on N-terminal amino acid, IL-8 and IP-10 are members of the CXC chemokine supergene family that attract neutrophils to the sites of inflammation [17], and MCP-1, MIP-1 α , MIP-1 β belong to the CC chemokine supergene family that attract monocytes and macrophages to the sites of inflammation [18]. Thus, MCP-1, MIP-1 α , and MIP-1 β were considered to induce monocytes to leave the bloodstream and enter thyroid tissues of PTC patients with HT to become tissue macrophages [19]. In addition, IL-8 and IP-10 induce neutrophils in HT*PTC patients, followed by inflammatory response and tissue damage [20].

In our research, mean production levels of chemokines (IL-8, IP-10, MCP-1, MIP-1 α , MIP-1 β) tended to be higher in thyroid para-cancerous tissues of HT⁺PTC patients compared with HT⁻PTC (P=0.003, P=0.001, P=0.026, P=0.001, P=0.001, respectively). Some researchers indicated that IP-10 might be a marker of host immune response due to a significant increase of IP-10 in Hashimoto's thyroiditis tissue specimens [21, 22], Visciano et al. proposed that IL-8 promoted thyroid carcinoma generation and angiogenesis [23]. Besides, the previous study revealed the effect of MIP-1 and MCP-1 on the development of autoimmune diseases, which was in agreement with our present work. These cytokines have been found in synoviocytes in rheumatoid arthritis and were thought to play a role in recruiting monocytes to joint inflammation (Villiger, 1992) [24]. Kemp confirmed expression of MCP-1, MIP-1 α , MIP-1 β , and IP-10 in all Hashimoto's disease and most Graves' disease thyroid specimens, whereas very little expression was detected in non-autoimmune goiter samples [25]. Although the present research indicated a high expression of these chemokines in patients with HT, their association with papillary thyroid carcinoma remains unknown.

The expression of ICAM-1 produced by thyroid cells can be enhanced by IL-1 [11], consistent with our experimental results. Buitrago et al. [26] showed that ICAM-1 was upregulated in PTC at the levels of both gene and protein expression. Moreover, this upregulated expression correlated with aggressive tumor features such as BRAF V600E mutation, extrathyroidal extension, and lymph node metastasis. The biological activity of IFN- γ is conventionally

linked to cytostatic and cytotoxic and antitumor mechanisms during the cell-mediated immune response [27]. Regarding tumor immunity, it is generally accepted that IFN- γ has an important role in tumor immune surveillance. In our study higher expression of INF- γ in para-cancerous tissue in HT*PTC indicated that the autoimmune condition might be beneficial for the host to surveille and constrict the tumor growth.

In conclusion, autoimmune HT was found to affect the cytokine profiles in patients with PTC by stimulating the secretion of Th1-type cytokines and chemokines. As most cytokines appear to have contradictory functions in tumor immune surveillance and autoimmunity, the exact regulatory mechanisms of cytokines and/ or chemokines between HT and PTC remain unclear. Further studies are needed to determine the significance of these findings and elucidate the interaction between chemokines and cytokines in the pathogenesis of PTC coexisting with HT.

Acknowledgements

This work was supported by College Students' Scientific and Technological Innovation Projects of Zhejiang Province (No. 2016R401259), and the Key project from the Health and Family Planning Commission of Zhejiang Province (No. 201510112).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Lei Xie, Department of Head and Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. Tel: 0086-571-86006186; Fax: 0086-571-86006186; E-mail: xieleisrrsh@163.com

References

- [1] Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
- [2] Dailey ME, Lindsay S and Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955; 70: 291-297.
- [3] Zhu F, Shen YB, Li FQ, Fang Y, Hu L and Wu YJ. The effects of hashimoto thyroiditis on lymph

node metastases in unifocal and multifocal papillary thyroid carcinoma: a retrospective Chinese cohort study. Medicine (Baltimore) 2016; 95: e2674.

- [4] Mehdizadeh R, Parizadeh MR, Khooei AR, Mehri S and Hosseinzadeh H. Cardioprotective effect of saffron extract and safranal in isoproterenol-induced myocardial infarction in wistar rats. Iran J Basic Med Sci 2013; 16: 56-63.
- [5] Kennedy RL and Jones TH. Cytokines in endocrinology: their roles in health and in disease. J Endocrinol 1991; 129: 167-178.
- [6] Jones TH. Interleukin-6 an endocrine cytokine. Clin Endocrinol (Oxf) 1994; 40: 703-713.
- [7] Papanicolaou DA, Wilder RL, Manolagas SC and Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
- [8] Bethin KE, Vogt SK and Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci U S A 2000; 97: 9317-9322.
- [9] Diamant M, Kayser L, Rasmussen AK, Bech K and Feldt-Rassmussen U. Interleukin-6 production by thyroid epithelial cells. Enhancement by interleukin-1. Autoimmunity 1991; 11: 21-26.
- [10] Zheng RQ, Abney E, Chu CQ, Field M, Grubeck-Loebenstein B, Maini RN and Feldmann M. Detection of interleukin-6 and interleukin-1 production in human thyroid epithelial cells by non-radioactive in situ hybridization and immunohistochemical methods. Clin Exp Immunol 1991; 83: 314-319.
- [11] Mine M, Tramontano D, Chin WW and Ingbar SH. Interleukin-1 stimulates thyroid cell growth and increases the concentration of the c-myc proto-oncogene mRNA in thyroid follicular cells in culture. Endocrinology 1987; 120: 1212-1214.
- [12] Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, Rebai A, Glasson E, Abid M, Ayadi F, Peraldi-Roux S and Ayadi H. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw 2012; 23: 101-106.
- [13] Ellyard JI, Simson L and Parish CR. Th2mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007; 70: 1-11.
- [14] Lee JH, Kim Y, Choi JW and Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol 2013; 168: 343-349.
- [15] Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG and Jain RK. Endothelial

focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A 2011; 108: 3725-3730.

- [16] Miccoli P, Torregrossa L, Borrelli N, Materazzi G, Cacciato Insilla A, Miccoli M and Basolo F. E-selectin expression and BRAF status in papillary thyroid carcinomas: correlation with clinicopathologic features. Surgery 2014; 156: 1550-1557; discussion 1557-1558.
- [17] Baggiolini M, Dewald B and Moser B. Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
- [18] Leonard EJ and Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990; 11: 97-101.
- [19] Deshmane SL, Kremlev S, Amini S and Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326.
- [20] Ajjan RA, Watson PF, McIntosh RS and Weetman AP. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol 1996; 105: 523-528.
- [21] Garcia-Lopez MA, Sancho D, Sanchez-Madrid F and Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86: 5008-5016.
- [22] Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E and Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651-658.
- [23] Visciano C, Liotti F, Prevete N, Cali G, Franco R, Collina F, de Paulis A, Marone G, Santoro M and Melillo RM. Mast cells induce epithelial-tomesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene 2015; 34: 5175-5186.
- [24] Villiger PM, Terkeltaub R and Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992; 149: 722-727.
- [25] Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF and Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003; 59: 207-213.
- [26] Buitrago D, Keutgen XM, Crowley M, Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T, Jin M, Fahey TJ 3rd and Zarnegar R. Intercellular adhesion molecule-1

(ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann Surg Oncol 2012; 19: 973-980.

[27] Schroder K, Hertzog PJ, Ravasi T and Hume DA. Interferon-gamma: an overview of signals,

mechanisms and functions. J Leukoc Biol 2004; 75: 163-189.